
Eloralintide (LY3841136) is a 37-amino-acid, fatty-acid-acylated amylin analog that acts as a full agonist at human AMY1R, the heterodimer of the calcitonin receptor (CTR) and receptor activity-modifying protein 1 (RAMP1). In engineered cells expressing one human receptor at a time, it raised AMY1R-dependent cAMP with an EC50 of 23.9 pM—about 12-fold more potently than at CTR and 11-fold more potently than at AMY3R—while reaching full agonism at all three receptors.[1] The AMY1R structures that explain how this peptide family engages a Gs-coupled active receptor are bound to CGRP and rat amylin, not to eloralintide.[2] The mechanism below therefore separates eloralintide’s measured pharmacology from the structural interpretation supplied by related ligands.
AMY1R Is a CTR–RAMP1 Heterodimer, Not a Standalone Receptor
AMY1R is a two-protein complex comprising CTR and RAMP1.[2] Pairing CTR with RAMP2 or RAMP3 produces AMY2R and AMY3R instead.[1] This shared CTR component makes the RAMP partnership relevant to subtype preference, but the eloralintide assays do not identify the particular contacts or conformational changes responsible for its AMY1R preference.
RAMP proteins can alter peptide recognition. Tethering RAMP1 or RAMP2 to the purified CTR extracellular domain increased binding of rat amylin, CGRP and the amylin antagonist AC413, supporting an allosteric contribution to affinity.[3] The same work found that the RAMP1 Trp-84 residue involved in CGRP recognition at the related CLR-based receptor was not required for rat amylin or AC413 binding in the CTR extracellular-domain system.[3] Residue-level explanations from CGRP receptor biology therefore cannot simply be assigned to eloralintide.
What the AMY1R Structures Show About Peptide Activation

Active AMY1R complexes bound to CGRP or rat amylin share an almost identical backbone architecture for the peptide N-terminus, residues 1–18, the heterotrimeric Gs protein and much of the receptor. Their extracellular domains differ slightly in orientation, including an approximately 1.5 Å translation in the CGRP-bound complex relative to the rat amylin-bound complex.[2] The peptides differ more substantially in their midregions, where a structural element termed the bypass motif is associated with the position and dynamics of the extracellular domain.[2]
The structures show two regions of peptide engagement rather than a single attachment point. The peptide C-terminus, residues 30–37, engages the extracellular domain, while the N-terminal loop occupies the upper transmembrane pocket. Accommodation of that loop involves outward movement of the tops of transmembrane helices TM6 and TM7 and extracellular loop 3, or ECL3. Conserved N-terminal interactions also involve TM3, TM5 and ECL2.[2]
These contacts have functional consequences. Alanine substitutions in ECL3 impaired rat amylin binding and peptide-mediated cAMP production; substitutions at Y372, R362, L368, P363 and D373 reduced rat amylin efficacy. A hydrogen bond between peptide threonine 6 and CTR histidine 302 is also identified as important for efficient receptor-mediated cAMP production across calcitonin-family peptides.[2]
The Gs-containing structures provide an active-state framework for interpreting eloralintide’s cAMP response. They do not directly demonstrate eloralintide’s bound conformation, Gs recruitment kinetics or the intervening molecular steps connecting its binding to cAMP accumulation. Its measured cAMP response is consistent with this Gs-coupled receptor architecture, not a direct observation of every signaling step.
The extracellular domain contributes to recognition as well. Experiments using a salmon calcitonin fragment and an AC413 antagonist fragment found that D101A and N135A substitutions abolished binding, while N124A reduced affinity by more than eightfold.[4] These results identify functionally important positions for the tested fragments; they do not establish those residues as eloralintide contacts.
The useful structural model is therefore a division of engagement between the extracellular domain and transmembrane pocket, with Gs associated with the active receptor. Assigning eloralintide an identical bypass motif or residue-by-residue contact map would go beyond that model.
How Eloralintide’s Human Receptor Data Compare Across AMY1R, AMY3R and CTR
The measured profile comes from UMUC3 cells engineered to express human AMY1R, human AMY3R or human CTR individually. The study measured ligand binding and cAMP accumulation separately; the values below are those reported for these receptor assays.[1]
| Human receptor (UMUC3 cells) | cAMP EC50 | Binding Ki | Reported Emax |
|---|---|---|---|
| AMY1R | 23.9 pM (SE 1.1) | 478.1 pM (SE 37.5) | >80% |
| AMY3R | 253.8 pM (SE 9.7) | 3608.9 pM (SE 356.8) | >80% |
| CTR | 291.0 pM (SE 27.0) | 3896.1 pM (SE 804.6) | >80% |
The study classified eloralintide as a full agonist at all three tested human receptors despite the different concentrations associated with their responses.[1] Preferential AMY1R activation therefore does not mean exclusive activation: the lower-potency receptors still responded fully in this assay system.
Rat receptor assays produced a different subtype profile. Eloralintide was about 45-fold more potent at rat AMY1R, with an EC50 of 5.4 pM, than at rat CTR, with an EC50 of 243.2 pM. Its potency preference over rat AMY3R, with an EC50 of 13.8 pM, was only about threefold. Binding affinity for rat AMY1R exceeded that for rat CTR by approximately 109-fold.[1] Thus, the rat profile includes relatively greater AMY3R activity than the human profile; it is not simply a uniformly stronger version of the human result.
Where the Selectivity Comes From
The binding and cAMP measurements establish a receptor preference, but they do not resolve its molecular origin. No eloralintide-bound structure or experiment mapping its subtype-selective receptor contacts is provided in the evidence supporting this article.
The human receptor table shows that preference is already present at the binding step, with a somewhat larger separation in functional potency. A larger potency than affinity gap would be consistent with more efficient Gs coupling at AMY1R, but these relative differences are close. Their separation is not evidence for an additional coupling mechanism without a direct test. The table supplies the measured values; the mechanistic conclusion is narrower: both binding and functional assays favor AMY1R, while the reason for that preference remains unresolved.[1]
Albumin binding adds another experimental variable. In the presence of 1% human serum albumin, the lipidated peptides eloralintide and cagrilintide showed reduced potency at human AMY1R, AMY3R and CTR. Non-lipidated rat amylin and salmon calcitonin showed no significant potency shifts. Eloralintide nevertheless retained its selectivity over human CTR.[1] Albumin conditions therefore matter when comparing potency measurements; the albumin-free results should not be treated as a direct description of peptide availability in tissues.
Assay design also affects what a selectivity claim covers. Receptor-specific Gs recruitment assays with other calcitonin-family agonists found that peptides behaving similarly at CTR and AMY1R could produce different responses at AMY2R and AMY3R.[5] Those experiments did not test eloralintide. They show why a subtype profile needs direct measurements rather than extrapolation from one receptor pair or signaling readout.
What the Chemical Modifications Change

Eloralintide’s main chain contains 37 amino acids, including three non-coded residues at positions 11, 15 and 22. Its reported chemical identity specifies L-configuration and a single enantiomer.[1] The principal structural features have distinct implications:
- A methylene thioacetal bridge connects Cys2 and Cys7 in place of the native disulfide bridge. The replacement enhances chemical stability.[1]
- Lys26 is acylated through a linker containing two gamma-glutamate residues to a saturated, linear C20 diacid. This side chain enables albumin binding as a strategy for extending pharmacokinetic half-life.[1]
- The C-terminus is amidated.[1]
Eloralintide keeps the 37-residue length and the two-cysteine bridge position while changing the bridge chemistry and adding the lipid. The demonstrated roles of the bridge replacement and lipid side chain concern chemical stability and albumin binding, respectively.[1] Those roles should not be confused with a demonstrated explanation for AMY1R selectivity.
In particular, the albumin experiment does not isolate the lipid’s contribution to receptor recognition. It shows a potency shift for the lipidated molecule in an albumin-containing environment, with selectivity over CTR retained.[1] It neither identifies a lipid–receptor contact nor establishes that the lipid and linker have no influence on binding. Likewise, listing the non-coded residues and amidated terminus does not establish what each contributes individually to subtype preference.
In the early human study, eloralintide had a reported half-life of 310–366 hours, or 12.9–15.3 days.[1] This is a pharmacokinetic observation, distinct from a receptor-binding measurement or an explanation of AMY1R activation.
Cells, Rats, Humans: What Each Evidence Layer Can Support
Cultured cells. Recombinant receptor assays establish the measured potency, affinity, maximal response and subtype comparisons in their respective cell systems.[1] Because the reported human comparisons use separately engineered receptor-expressing cells, they do not identify which receptor dominates a response in tissue containing multiple receptor types.
Rats. Eloralintide reduced food intake and body weight in lean and diet-induced obese rats. In the latter model, fat mass accounted for approximately 68–85% of total weight loss across the tested experimental conditions. Eloralintide-treated rats also showed less conditioned taste avoidance than cagrilintide-treated rats.[1] These are organism-level animal findings, not direct demonstrations that AMY1R alone caused the observed responses. Conditioned taste avoidance is also not a human tolerability result.
Humans. A phase 1 randomized, placebo-controlled, participant- and investigator-blinded trial in healthy participants, NCT05295940, evaluated safety, tolerability and pharmacokinetics.[1] The human discussion here is confined to those early safety and pharmacokinetic observations. Neither the cell comparisons nor the rat findings are presented as human efficacy evidence.
What Would Confirm the Mechanism
An eloralintide-bound AMY1R structure would allow direct comparison of its terminal contacts and midregion organization with the related-peptide structures. Complementary experiments testing the relevant receptor and ligand positions would be needed to distinguish a binding contact from a feature that actually determines subtype preference. These are proposed ways to resolve the mechanism, not completed eloralintide findings.
At the organism level, the eloralintide study identifies further characterization of in vivo selectivity as necessary and notes that the physiological roles of individual amylin receptor subtypes remain incompletely understood.[1] The supported answer is therefore specific: eloralintide binds preferentially to human AMY1R and produces a full cAMP response in engineered cells. Related AMY1R structures explain the general architecture of peptide engagement and Gs association, but not yet the exact contacts that give this analog its preference.
Related research: Cagrilintide vs Eloralintide: Receptor Profiles and Research Comparisons; Eloralintide vs Cagrilintide: Structure, Selectivity, PK and How to Tell Them Apart (2026); Eloralintide vs Retatrutide: Amylin (AMY1R) vs Triple Agonist — Research Comparison; What Is Eloralintide.
Research Use Only. This article summarizes published receptor pharmacology for laboratory research and analytical education only. It is not a validated experimental protocol or medical or veterinary advice, and it does not support human or animal administration or personal preparation.
References
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- Cryo-EM Structure of the Human Amylin 1 Receptor in Complex with CGRP and Gs Protein
- Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: Insights into Peptide-Binding Modes and Allosteric Modulation of the Calcitonin Receptor by Receptor Activity-Modifying Proteins
- Amylin Receptor 1 Mutagenesis Revealed a Potential Role of Calcitonin Serine 29 in Receptor Interaction
- Development of a Novel Assay for Direct Assessment of Selective Amylin Receptor Activation Reveals Novel Differences in Behavior of Selective and Nonselective Peptide Agonists